COMPARISON OF SAFETY OF LATANOPROST WITH PRESERVATIVE BENZALKONIUM CHLORIDE (BAK) VERSUS BAK-FREE TRAVOPROST IN PRIMARY OPEN-ANGLE GLAUCOMA

Authors

  • POOJA JUNEJA Department of Pharmacology, Bhagat Phool Singh Government Medical College for Women, Khanpur Kalan - 131 305, Sonepat, Haryana, India.
  • SEEMA RANI Department of Pharmacology, Bhagat Phool Singh Government Medical College for Women, Khanpur Kalan - 131 305, Sonepat, Haryana, India.
  • ANUPAMA TANDON Department of Ophthalmology, Bhagat Phool Singh Government Medical College for Women, Khanpur Kalan - 131 305, Sonepat, Haryana, India.
  • GARIMA BHUTANI Department of Pharmacology, Bhagat Phool Singh Government Medical College for Women, Khanpur Kalan - 131 305, Sonepat, Haryana, India.
  • RAHUL SAINI Department of Pharmacology, Bhagat Phool Singh Government Medical College for Women, Khanpur Kalan - 131 305, Sonepat, Haryana, India.

DOI:

https://doi.org/10.22159/ajpcr.2022.v15i7.44829

Keywords:

Primary open-angle glaucoma, Latanoprost, Travoprost, Benzalkonium chloride, Schirmer test, Tear break-up time, Ocular surface disease index

Abstract

Objective: The objective of this study was to compare the safety of BAK-preserved latanoprost versus travoprost BAK-free ophthalmic solution in the primary open-angle glaucoma (POAG).

Methods: Prospective, open-labeled, and randomized comparative study conducted in tertiary care hospital. Forty patients were enrolled and divided into 20 patients in each group: Group A topical latanoprost (0.005%) with BAK and Group B topical BAK-free travoprost (0.004%). Safety assessment was done by following parameters – Schrimer test (ST), tear break-up time (TBUT), and ocular surface disease index (OSDI).

Results: ST and TBUT were calculated at baseline, 1 month, 2 months, 3 months, and 4 months and OSDI scores were calculated at baseline, 2 months and 4 months. Group A and B were compared using ST, TBUT, and OSDI scores. Group B showed statistically significant results (p<0.05).

Conclusion: Topical BAK-free travoprost is more tolerable than BAK-preserved latanoprostin POAG.

Downloads

Download data is not yet available.

References

Khurana AK. Comprehensive Opthalmology. 6th ed. Rohtak: New International Pvt. Ltd.; 2015. p. 214-215.

Allison K, Patel D, Alabi O. Epidemiology of glaucoma: The past, present, and predictions for the future. Cureus 2020;12:e11686. doi: 10.7759/cureus.11686, PMID 33391921

Senjam SS. Glaucoma blindness-a rapidly emerging non-communicable ocular disease in India: Addressing the issue with advocacy. J Fam Med Prim Care 2020;9:2200-6. doi: 10.4103/jfmpc. jfmpc_111_20, PMID 32754474

Bagnis A, Papadia M, Scotto R, Traverso CE. Antiglaucoma drugs: The role of preservative-free formulations. Saudi J Ophthalmol 2011;25:389-94. doi: 10.1016/j.sjopt.2011.08.004, PMID 23960953

Kumar G, Chaurasia RC, Singh SP. Efficacy and adverse effects of topical latanoprost with respect to preservative in patients of POAG. J Clin Diagn Res 2018;12:FC06-9. doi: 10.7860/JCDR/2018/29284.11891

Jayanthi CR, Divyasree RN, Sujitha BL. Efficacy and safety of topical BAK-free travoprost 0.004% versus BAK-preserved travoprost 0.004% in the treatment of primary open angle glaucoma: A comparative study at a tertiary care hospital. Int J Basic Clin Pharmacol 2017;6:2199-205. doi: 10.18203/2319-2003.ijbcp20173744

Kurna SA, Acikgoz S, Altun A, Ozbay N, Sengor T, Olcaysu OO. The effects of topical antiglaucoma drugs as monotherapy on the ocular surface: A prospective study. J Ophthalmol 2014;2014:460483.

Dibajnia P, Mohammadinia M, Moghadasin M, Amiri MA. Tear film break-up time in bipolar disorder. Iran J Psychiatry 2012;7:191-3. PMID 23408791

Ozcura F, Aydin S, Helvaci MR. Ocular surface disease index for the diagnosis of dry eye syndrome. Ocul Immunol Inflamm 2007;15:389-93. doi: 10.1080/09273940701486803, PMID 17972223

Chhabra H, Gupta A, Singh G. A comparative study of benzalkonium chloride-free latanoprost versus benzalkonium chloride-preserved latanoprost on ocular surface health in patients of primary open angle glaucoma. Int J Basic Clin Pharmacol 2017;6:1110-4. doi: 10.18203/2319-2003.ijbcp20171660

El Hajj Moussa WG, Farhat RG, Nehme JC, Sahyoun MA, Schakal AR, Jalkh AE, et al. Comparison of efficacy and ocular surface disease index score between bimatoprost, latanoprost, travoprost, and tafluprost in glaucoma patients. J Ophthalmol 2018;2018:1319628. doi: 10.1155/2018/1319628, PMID 29707390

Lopes JF, Hubatsch DA, Amaris P. Effect of benzalkonium chloride-free travoprost on intraocular pressure and ocular surface symptoms in patients with glaucoma previously on latanoprost: An open-label study. BMC Ophthalmol 2015;15:166. doi: 10.1186/s12886-015-0151-7, PMID 26563363

Published

07-07-2022

How to Cite

JUNEJA, P., SEEMA RANI, A. TANDON, G. BHUTANI, and R. SAINI. “COMPARISON OF SAFETY OF LATANOPROST WITH PRESERVATIVE BENZALKONIUM CHLORIDE (BAK) VERSUS BAK-FREE TRAVOPROST IN PRIMARY OPEN-ANGLE GLAUCOMA”. Asian Journal of Pharmaceutical and Clinical Research, vol. 15, no. 7, July 2022, pp. 103-6, doi:10.22159/ajpcr.2022.v15i7.44829.

Issue

Section

Original Article(s)